Compare Corsair Gaming Inc (CRSR) vs TG Therapeutics Inc (TGTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Corsair Gaming Inc vs TG Therapeutics Inc — how do they compare? Corsair Gaming Inc trades at $13.45 (market cap $1.40B), while TG Therapeutics Inc trades at $47.68 (market cap $7.58B). The key difference: TG Therapeutics Inc is far larger — about 5.4× Corsair Gaming Inc's market cap, and Corsair Gaming Inc is trading nearer its 52-week high, TG Therapeutics Inc nearer its low. Which is the better fit depends on your goals.
| CRSR | TGTX | |
|---|---|---|
Market Cap | $1.40B | $7.58B |
Sector | Technology | Health |
52-Week High | $14.35 | $59.06 |
52-Week Low | $4.58 | $26.94 |
Enterprise Value | $1.39B | $7.78B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Corsair Gaming (CRSR) trades at $13.45, up 4.83% today, with a bullish technical signal from moving averages and recent earnings beats. The company reported strong Q2 2026 results, exceeding EPS expectations, and raised full-year guidance. Revenue trends show recovery, with 2026 projected net income margin at 2.53%, though 2025 saw a net loss. Analyst consensus is mixed with a $12.40 price target, below the current price.
Outlook is cautiously optimistic due to earnings momentum and AI product initiatives, but risks include competitive pressures and valuation concerns with a P/E of 41.68. Investors should weigh growth potential against high expectations and historical profitability volatility.
TG Therapeutics (TGTX) trades at $49.50, down 0.8% with a bearish technical signal. The company reported strong revenue growth with Q2 2026 sales reaching $240 million and raised full-year guidance to $950 million, though earnings have missed expectations for three consecutive quarters. Analyst consensus remains bullish with 84.6% buy ratings and a $63.75 price target, representing 29% upside potential from current levels.
The outlook is mixed with strong revenue momentum from BRIUMVI offset by earnings misses and negative cash flow. Key risks include ongoing earnings underperformance, shareholder litigation, and high valuation multiples. The stock offers growth potential but requires careful monitoring of execution and profitability trends.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Corsair Gaming Inc
Corsair Gaming Inc is engaged in the business of providing high-performance gear for gamers and content creators. The product portfolio includes Cases, Keyboards, Mice, Headsets, Power Supplies, Gaming Computers, Gaming Chairs, Mousepads, and other related products. The company operates in two segments namely, Gamer and Creator peripherals, which is the key revenue generating segment
Read more on CRSR →About TG Therapeutics Inc
TG Therapeutics is a fully integrated biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases. Its cornerstone product, BRIUMVI (ublituximab-xiiy), is a glycoengineered monoclonal antibody approved for relapsing forms of multiple sclerosis. The company is currently executing a 'pipeline-in-a-product' strategy, expanding BRIUMVI into new delivery methods and indications while advancing a broader portfolio of autoimmune and oncology candidates.
Read more on TGTX →
